Last reviewed · How we verify
cisplatin or carboplatin + pemetrexed
This combination uses platinum-based chemotherapy (cisplatin or carboplatin) plus pemetrexed, a folate antagonist that inhibits multiple enzymes in nucleotide synthesis, to damage cancer cell DNA and disrupt cell division.
This combination uses platinum-based chemotherapy (cisplatin or carboplatin) plus pemetrexed, a folate antagonist that inhibits multiple enzymes in nucleotide synthesis, to damage cancer cell DNA and disrupt cell division. Used for Non-small cell lung cancer (likely in combination with immunotherapy, given Immutep's focus on LAG-3 immunotherapy).
At a glance
| Generic name | cisplatin or carboplatin + pemetrexed |
|---|---|
| Sponsor | Immutep S.A.S. |
| Drug class | Platinum-based chemotherapy + antifolate antimetabolite combination |
| Target | DNA (platinum agents); thymidylate synthase, dihydrofolate reductase, GARFT (pemetrexed) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin and carboplatin are platinum compounds that form DNA adducts and cross-links, leading to apoptosis. Pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, disrupting purine and pyrimidine synthesis. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Non-small cell lung cancer (likely in combination with immunotherapy, given Immutep's focus on LAG-3 immunotherapy)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Nephrotoxicity
- Peripheral neuropathy
- Anemia
- Mucositis
Key clinical trials
- Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer (PHASE2)
- Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (PHASE1, PHASE2)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors (PHASE1)
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC (PHASE3)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cisplatin or carboplatin + pemetrexed CI brief — competitive landscape report
- cisplatin or carboplatin + pemetrexed updates RSS · CI watch RSS
- Immutep S.A.S. portfolio CI